NCT02497937View on ClinicalTrials.gov

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 13, 2016

Primary Completion Date

August 21, 2017

Study Completion Date

August 21, 2017

Conditions
Heart Failure
Interventions
DRUG

GSK2798745

GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.

DRUG

Placebo

Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.

Trial Locations (2)

55415

GSK Investigational Site, Minneapolis

55905

GSK Investigational Site, Rochester

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02497937 - A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure | Biotech Hunter | Biotech Hunter